

Table S1. Unadjusted Urine Arsenic levels (inorganic and methylated) by subgroups in SOLNAS ^a.

	Median(IQRs)
Overall(n=45)	9.1(5.5,18.5)
Site	
Bronx(n=11)	16.3(10.2,19.8)
Chicago(n=11)	8.1(5.9,17.5)
Miami(n=11)	10.0(6.0,20.0)
San Diego(n=12)	7.2(3.0,10.4)
Ethnicity	
Caribbean(n=26)	12.8(6.4,19.5)
Mainland(n=19)	8.7(4.0,16.3)
Obesity status	
Non-obese(n=32)	8.2(5.5,17.3)
Obese(n=13)	16.3(8.9,18.7)
Daily rice intake	
Low(n=22)	9.3(4.7,16.8)
High(n=23)	9.1(6.6,19.9)
Folate biomarker	
Low(n=23)	16.6(7.1,19.9)
High(n=22)	7.5(5.0,13.8)

^a Arsenic not derived from seafood estimated using sum of inorganic and methylated arsenic species applying a residual-based method to remove the impact of seafood arsenicals using urine arsenobetaine, a seafood arsenical that correlates with other seafood arsenicals (previously validated in Jones et al. Am J Epidemiol 2016).

Table 2. Mean, median, range of absolute change in urinary arsenic (As) species for each analyte by visit ^a among 20 subjects with repeated measurements in select cohort of Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

	SOLNAS Visit	Mean (SD)	Median (IQR)	Minimum	Max
Σ As*, μ g/L	2 vs 1	-1.97 (4.97)	-1.92 (-3.46, -0.58)	-12.21	11.66
	3 vs 1	0.49 (6.88)	-0.79 (-4.84, 5.16)	-10.74	15.42
Inorganic As (iAs), μg/L	2 vs 1	-0.18 (0.73)	-0.10 (-0.30, -0.04)	-2.45	1.32
	3 vs 1	0.22 (1.01)	0.05 (-0.28, 0.50)	-2.21	3.05
Monomethylated As (MMA), μg/L	2 vs 1	-0.46 (1.22)	-0.28 (-0.91, -0.12)	-4.17	2.94
	3 vs 1	0.20 (1.53)	-0.02 (-0.68, 0.97)	-3.47	3.23
Dimethylated As (DMA), μg/L	2 vs 1	-4.73 (8.32)	-3.75 (-5.73, 0.03)	-27.50	9.83
	3 vs 1	-1.52 (9.97)	-1.64 (-6.53, 3.90)	-20.93	15.81
iAs %	2 vs 1	0.03 (5.03)	0.33 (-2.66, 1.85)	-8.61	14.76
	3 vs 1	0.95 (3.04)	0.93 (-0.81, 2.33)	-5.33	9.07
MMA%	2 vs 1	-0.02 (3.69)	-0.12 (-2.49, 1.71)	-6.73	7.86
	3 vs 1	0.90 (3.74)	0.44 (-1.03, 4.25)	-6.95	7.98
DMA%	2 vs 1	-0.35 (6.73)	0.18 (-4.72, 3.51)	-13.76	12.32
	3 vs 1	-1.91 (5.66)	-1.32 (-5.48, 1.57)	-12.92	8.71

^a SOLNAS visits correspond to 1st visit for SOLNAS Ancillary Study, second visit (6-12 days later) and third visit (6-12 months later). *Arsenic not derived from seafood (Σ As) estimated using sum of inorganic and methylated arsenic species applying a residual-based method to remove the impact of seafood arsenicals using urine arsenobetaine, a seafood arsenical that correlates with other seafood arsenicals (previously validated in Jones et al. Am J Epidemiol 2016).

Table 3. Comparison of median (IQR) of urinary arsenic (As) species for each analyte in select cohort of Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and Hispanic/Latino participants in the MESA study¹.

Urine arsenic measures, µg/L	HCHS/SOL (n=45) Median (IQR)	MESA Hispanic/Latinos (n=75) Median (IQR)
ΣAs	6.0 (4.3, 10.5)	3.9 (2.4, 6.2)
Inorganic As (iAs)	0.6 (0.4, 1.0)	0.1 (0.1, 0.4)
Monomethylarsonic acid (MMA)	1.2 (0.7, 1.9)	0.4 (0.2, 0.6)
Dimethylarsinic acid (DMA)	7.2 (4.3, 15.3)	3.1 (2.1, 5.3)

ΣAs: sum of inorganic and methylated arsenic species. ¹ Jones, M.R., et al., Ethnic, geographic and dietary differences in arsenic exposure in the multi-ethnic study of atherosclerosis (MESA). J Expo Sci Environ Epidemiol, 2018.